Immix Biopharma, Inc. (IMMX)
USD 2.1
(-8.3%)
USD 2.1
(-8.3%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | -89.51 Million | - | - | - |
| Cost of Revenue | 5468.00 | 2135.00 | 2468.00 | 2321.00 | 1082.00 |
| Gross Profit | -5468.00 | -89.51 Million | -2468.00 | -2321.00 | -1082.00 |
| Operating Expenses | 16.14 Million | 8.21 Million | 1.35 Million | 453.85 Thousand | 842.49 Thousand |
| Selling, General and Administrative Expenses | 7.4 Million | 4.02 Million | 1.22 Million | 205.7 Thousand | 259.33 Thousand |
| Research and Development Expenses | 8.73 Million | 4.19 Million | 126.52 Thousand | 248.14 Thousand | 583.16 Thousand |
| Other Expenses | - | - | - | 512.00 | 224.00 |
| Cost and Expenses | 16.14 Million | 8.21 Million | 1.35 Million | 453.85 Thousand | 842.49 Thousand |
| Operating Income | -16.14 Million | -8.21 Million | -1.35 Million | -453.85 Thousand | -842.49 Thousand |
| Interest Expense | - | 497.00 | 179.85 Thousand | 101.97 Thousand | 109.98 Thousand |
| Income Tax Expense | 26.41 Thousand | 10.26 Thousand | 6013.00 | 17.54 Thousand | 20.55 Thousand |
| Earnings before Tax | -15.56 Million | -8.21 Million | -24.37 Million | -1.13 Million | -952.25 Thousand |
| Net Income | -15.42 Million | -8.22 Million | -24.38 Million | -1.14 Million | -972.81 Thousand |
| Earnings Per Share Basic | -0.89 | -0.62 | -1.84 | -0.15 | -0.29 |
| Earnings Per Share Diluted | -0.89 | -0.62 | -1.84 | -0.15 | -0.29 |
| Weighted Average Shares Outstanding | 17.34 Million | 13.22 Million | 13.22 Million | 7.77 Million | 3.37 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.34 Million | 13.22 Million | 13.22 Million | 7.77 Million | 3.37 Million |
| Gross Margin | - | 1.00 | - | - | - |
| EBIT Margin | - | 0.09 | - | - | - |
| Profit Margin | - | 0.09 | - | - | - |
| EBITDA | -16.13 Million | -8.21 Million | -1.34 Million | -451.53 Thousand | -841.19 Thousand |
| Earnings Before Tax Margin | - | 0.09 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 4784.00 | - | - |
| Cost of Revenue | 24.29 Thousand | 23.85 Thousand | 5468.00 | 3076.00 | 1381.00 | 506.00 |
| Gross Profit | -24.29 Thousand | -23.85 Thousand | -5468.00 | 1708.00 | -1381.00 | -506.00 |
| Operating Expenses | 4.69 Million | 5.6 Million | 16.13 Million | 5.36 Million | 4.52 Million | 3.72 Million |
| Selling, General and Administrative Expenses | 2.47 Million | 2.35 Million | - | 2.26 Million | 2.41 Million | 1.51 Million |
| Research and Development Expenses | 2.22 Million | 3.24 Million | - | 3.1 Million | 2.1 Million | 2.2 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 4.72 Million | 5.62 Million | 16.14 Million | 5.36 Million | 4.52 Million | 3.72 Million |
| Operating Income | -4.72 Million | -5.62 Million | -16.14 Million | -5.36 Million | -4.52 Million | -3.72 Million |
| Interest Expense | - | - | - | 46.26 Thousand | - | - |
| Income Tax Expense | 10.26 Thousand | 8839.00 | 26.41 Thousand | 8089.00 | 6807.00 | 6349.00 |
| Earnings before Tax | -4.39 Million | -5.32 Million | -15.56 Million | -5.14 Million | -4.33 Million | -3.59 Million |
| Net Income | -4.39 Million | -5.25 Million | -15.42 Million | -5.08 Million | -4.28 Million | -3.57 Million |
| Earnings Per Share Basic | -0.15 | -0.22 | - | -0.26 | -0.23 | -0.24 |
| Earnings Per Share Diluted | -0.15 | -0.22 | - | -0.26 | -0.23 | -0.24 |
| Weighted Average Shares Outstanding | 28.78 Million | 23.43 Million | 17.34 Million | 19.92 Million | 18.57 Million | 15.03 Million |
| Weighted Average Shares Outstanding (Diluted) | 28.78 Million | 23.43 Million | 17.34 Million | 19.92 Million | 18.57 Million | 15.03 Million |
| Gross Margin | - | - | - | 0.36 | - | - |
| EBIT Margin | - | - | - | -1121.53 | - | - |
| Profit Margin | - | - | - | -1063.86 | - | - |
| EBITDA | -4.69 Million | -5.6 Million | - | -5.36 Million | -4.33 Million | -3.59 Million |
| Earnings Before Tax Margin | - | - | - | -1122.18 | - | - |
ZODIAC
THEMISMED
BNL
4215
WKPPF
SEB